← Leaderboards
Raman Bahal
University Of Connecticut Storrs
$2,703,154
Attributed
$3,164,507
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $631.8K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,164,507 · 4
By mechanism
R01$2,520,325 · 2
R21$402,682 · 1
U18$241,500 · 1
Top collaborators
- Andrew J Wiemer2 shared
- Rajkumar Verma1 shared
Most similar at University Of Connecticut Storrs
Same institution · by research overlap
- Andrew J Wiemer$4,146,227
- Laijun Lai$5,623,060
Others in their field
Other Emerging Leaders on “Binding”
- Xinhua Li · Nano Terra, Inc.$35,520,438
- John Damon Chodera · Sloan-Kettering Inst Can Research$21,305,909
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Kristian Graugaard Andersen · Scripps Research Institute, The$18,732,618
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
BindingMediatingToxic EffectIn VivoMouse ModelPeptidesResistanceDesignCellsClinical ApplicationInnovationNanoparticleSiteFormulationSpecificityNucleic Acid AnalogNucleic AcidsAffinityNext GenerationPeptide Nucleic AcidsModificationBiomaterial CompatibilityGene ExpressionGlycolates
Grant awards (9)
Developing next-generation RNA inhibitors for stroke therapy$520,025
R01 · FY2025 · NS
Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing$402,500
R01 · FY2024 · HL · contact PI
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy$214,513
R21 · FY2024 · CA
Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing$402,500
R01 · FY2023 · HL · contact PI
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy$188,169
R21 · FY2023 · CA
Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing$402,500
R01 · FY2022 · HL · contact PI
Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing$402,500
R01 · FY2021 · HL · contact PI
Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing$390,300
R01 · FY2020 · HL · contact PI
Nanodelivery therapeutic systems for substance use disorder$241,500
U18 · FY2020 · DA · contact PI